CAESAREA, Israel, June 5, 2017 /PRNewswire/ -- DarioHealth Corp.
(NASDAQ: DRIO), a leading global digital health company with mobile
health and big data solutions, today announced that it is launching
a new social initiative called DarioCares™ at the American Diabetes
Association's (ADA) 77th Scientific Sessions in San Diego later this week.
The aim of DarioCares™ is to leverage DarioHealth's compelling
offerings and to raise funds for charitable and non-profit
organizations working in the field of diabetes. DarioHealth will
donate a portion of the proceeds of every sale made from this
channel to organizations that will participate in our DarioCares™
plan. DarioHealth is currently in discussions with various
organizations that may participate in the DarioCares™ program. In
addition, DarioHealth intends to work closely with each
participating organization to fine tune the right messaging in
effort to maximize the impact of diabetes awareness.
Organizations that are accepted into the DarioCares™ program
will have an unprecedented opportunity to raise diabetes awareness
and further their cause by promoting the acclaimed Dario™ Blood
Glucose Monitoring System. The all-in-one blood glucose meter and
native smartphone app provides people with diabetes and
pre-diabetes with a unique method to check their blood glucose
levels via their iPhone.
Erez Raphael, Chairman and CEO of
DarioHealth, commented, "The ADA conference is one of the biggest
annual events in the diabetes industry. Many NGOs will be there and
we look forward to strengthening our relationships with them and
raising diabetes awareness. Furthermore, DarioCares™ is an
excellent chance to play an active role with leading organizations
that are driving change for people with diabetes. This is a win-win
opportunity where we can make a significant contribution to the
diabetes community."
For more information about DarioCares™, please visit DarioHealth
at the ADA in booth 443. The ADA's 77th Scientific Sessions will
take place June 9 - 13, 2017, at the
San Diego Convention Center in
San Diego, California.
About DarioHealth Corp.
DarioHealth Corp. is a leading global digital health company
serving tens of thousands of users with dynamic mobile health
solutions. We believe people deserve the best tools to manage their
treatment, and harnessing big data, we have developed a unique way
for our users to analyze and personalize their diabetes management.
With our smart diabetes solution, users have direct access to track
and monitor all facets of diabetes, without having the disease slow
them down. The acclaimed Dario™ Blood Glucose Monitoring System
all-in-one blood glucose meter and native smartphone app gives
users an unrivaled method for self-diabetes management. DarioHealth
is headquartered in Caesarea,
Israel with a regional office in Burlington, Massachusetts. For more
information, visit http://mydario.investorroom.com/.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company describes
the launch of its DarioCares™ plan and its contributions and the
Company's intention to donate a portion of the proceeds of every
sale made through the DarioCares™ plan to participating
organizations, it is using forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™) may differ
significantly from those set forth in the forward-looking
statements. The Company undertakes no obligation to publicly update
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
applicable law.
DarioHealth Corporate and Media Contact
Shmuel Herschberg
Marketing Director
shmuel@mydario.com
1-914-775-5548
DarioHealth Investor Relations Contact
Hayden IR
Rob Fink / Brett Maas
DRIO@HaydenIR.com
646-415-8972 / 646-536-7331
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/dariohealth-launching-new-social-initiative-at-adas-77th-scientific-sessions-300468471.html
SOURCE DarioHealth Corp.